Phase II clinical trial - Pédiatrie Tumeurs cérébrales
CDRB436G2201
Pédiatrie Tumeurs cérébrales
Essai clinique fermé
Public cible
Enfant
Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)
Description de l'essai
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
Liens utiles
ISABELLE AERTS
Investigateur principal